- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07754461
A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar
A Phase III, Randomised, Double-blind, Parallel-group, 56-week Study, Evaluating the Efficacy and Safety of Survodutide (BI 456906), Compared With Placebo, in Participants With Type 2 Diabetes, as an Adjunct to Diet and Physical Activity Alone or in Combination With Either Oral Antidiabetic Medications or Insulin
This study aims to find out whether a study medicine called survodutide helps people control their blood sugar. Adults who live with type 2 diabetes and with a body mass index (BMI) of 23 kg/m2 or higher can join.
The study has 3 parts. In each part the study compares survodutide with placebo. Survodutide is being developed to treat several health problems including type 2 diabetes. Placebo looks like survodutide but does not contain any medicine.
Depending on a person's diabetes treatment, a person will be assigned either to
- Part A: healthy eating and physical activity
- Part B: diabetes tablets (no injection of insulin)
- Part C: injection of insulin (with or without diabetes tablets)
Participants are randomly put into 1 of 3 groups, which means the group is chosen by chance. Two groups of participants get survodutide at different dose levels, and the third group gets placebo as injection under the skin once a week. You have a 2 in 3 chance of getting survodutide. During the study, participants continue their regular diabetes treatment.
Participants are in the study for about 1 year and 2 months. During this time, they attend up to 12 visits at the site and receive at least 9 phone calls. Study doctors regularly test participants' blood sugar by checking their HbA1c values and other laboratory test results. The study doctor also regularly checks participants' health and takes note of any changes. For each study part, the results will be compared between the survodutide and the placebo group to see whether the treatment works.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 3
Kontakter och platser
Studiekontakt
- Namn: Boehringer Ingelheim
- Telefonnummer: 1-800-243-0127
- E-post: clintriage.rdg@boehringer-ingelheim.com
Studieorter
-
-
New South Wales
-
Camperdown, New South Wales, Australien, 2050
- Rekrytering
- Royal Prince Alfred Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 1800271035
- E-post: australia@bitrialsupport.com
-
-
Queensland
-
Meadowbrook, Queensland, Australien, 4131
- Har inte rekryterat ännu
- Logan Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 1800271035
- E-post: australia@bitrialsupport.com
-
-
South Australia
-
Oaklands Park, South Australia, Australien, 5046
- Rekrytering
- Southern Adelaide Diabetes & Endocrine services
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 1800271035
- E-post: australia@bitrialsupport.com
-
-
Victoria
-
Melbourne, Victoria, Australien, 3004
- Har inte rekryterat ännu
- Baker Heart and Diabetes Institute
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 1800271035
- E-post: australia@bitrialsupport.com
-
-
-
-
Alabama
-
Birmingham, Alabama, Förenta staterna, 35235
- Upphängd
- Cahaba Research, Inc. - Trussville Location
-
-
Arizona
-
Gilbert, Arizona, Förenta staterna, 85296
- Har inte rekryterat ännu
- Mission Research Institute - Gilbert
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Paradise Valley, Arizona, Förenta staterna, 85253
- Upphängd
- Helios Clinical Research - Paradise Valley
-
Phoenix, Arizona, Förenta staterna, 85028
- Upphängd
- Helios Clinical Research - Phoenix
-
-
Arkansas
-
Little Rock, Arkansas, Förenta staterna, 72211
- Upphängd
- Woodland International Research Group, Inc.
-
-
California
-
Canoga Park, California, Förenta staterna, 91304
- Har inte rekryterat ännu
- San Fernando Valley Health
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Concord, California, Förenta staterna, 94520
- Upphängd
- John Muir Physician Network Clinical Research Center
-
Escondido, California, Förenta staterna, 92025
- Upphängd
- Neighborhood Healthcare - Escondido
-
Lincoln, California, Förenta staterna, 95648
- Upphängd
- Clinical Trials Research - Lincoln
-
Long Beach, California, Förenta staterna, 90815
- Upphängd
- ARK Clinical Research
-
Northridge, California, Förenta staterna, 91325
- Upphängd
- Valley Clinical Trials, Inc.
-
Spring Valley, California, Förenta staterna, 91978
- Upphängd
- Encompass Clinical Research, Spring Valley
-
Walnut Creek, California, Förenta staterna, 94598
- Upphängd
- Diablo Clinical Research
-
West Hills, California, Förenta staterna, 91307
- Upphängd
- Focus Clinical Research
-
-
Florida
-
Clearwater, Florida, Förenta staterna, 33765
- Upphängd
- Clinical Research of West Florida, Inc.
-
Fort Myers, Florida, Förenta staterna, 33912
- Upphängd
- Covenant Metabolic Specialists, LLC - Fort Myers
-
Hollywood, Florida, Förenta staterna, 33024
- Upphängd
- Encore Medical Research
-
Lakeland, Florida, Förenta staterna, 33803
- Upphängd
- Accel Research Sites - Lakeland
-
Lakeland, Florida, Förenta staterna, 33805
- Upphängd
- Clinical Research of Central Florida - Lakeland
-
Largo, Florida, Förenta staterna, 33777
- Upphängd
- Tampa Bay Medical Research - Largo
-
Miami, Florida, Förenta staterna, 33165
- Upphängd
- New Horizon Research Center-Miami-69732
-
Riverview, Florida, Förenta staterna, 33578
- Upphängd
- Covenant Metabolic Specialists, LLC - Brandon
-
University Park, Florida, Förenta staterna, 34201
- Upphängd
- Covenant Metabolic Specialists, LLC - Sarasota
-
Weston, Florida, Förenta staterna, 33331
- Upphängd
- Encore Medical Research - Weston
-
Winter Park, Florida, Förenta staterna, 32789
- Upphängd
- Conquest Research
-
-
Georgia
-
Columbus, Georgia, Förenta staterna, 31904
- Upphängd
- Centricity Research, Endocrine Consultants
-
Fayetteville, Georgia, Förenta staterna, 30214
- Upphängd
- Javara-Fayetteville-67354
-
Lawrenceville, Georgia, Förenta staterna, 30046
- Har inte rekryterat ännu
- Balanced Life Health Care Solutions
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Union City, Georgia, Förenta staterna, 30291
- Har inte rekryterat ännu
- Rophe Adult and Pediatric Medicine
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Hawaii
-
Honolulu, Hawaii, Förenta staterna, 96817
- Har inte rekryterat ännu
- Pacific Diabetes & Endocrine Center
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Idaho
-
Blackfoot, Idaho, Förenta staterna, 83221
- Upphängd
- Elite Clinical Trials - Blackfoot
-
Idaho Falls, Idaho, Förenta staterna, 83404
- Har inte rekryterat ännu
- Family First Clinical Research
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Meridian, Idaho, Förenta staterna, 83646
- Har inte rekryterat ännu
- Solaris Clinical Research
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Kentucky
-
Lexington, Kentucky, Förenta staterna, 40509
- Upphängd
- AMR Lexington
-
-
Maryland
-
Rockville, Maryland, Förenta staterna, 20852
- Har inte rekryterat ännu
- Endocrine and Metabolic Consultants
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Michigan
-
Buckley, Michigan, Förenta staterna, 49620
- Har inte rekryterat ännu
- Northern Pines Health Center - Buckley
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Dearborn, Michigan, Förenta staterna, 48126
- Upphängd
- Revival Research Institute, LLC - Dearborn
-
Troy, Michigan, Förenta staterna, 48098
- Upphängd
- Arcturus Healthcare - Troy Internal Medicine Research Division
-
-
Minnesota
-
Minneapolis, Minnesota, Förenta staterna, 55416
- Har inte rekryterat ännu
- International Diabetes Center
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Mississippi
-
Olive Branch, Mississippi, Förenta staterna, 38654
- Upphängd
- Olive Branch Family Medical Center
-
-
Montana
-
Kalispell, Montana, Förenta staterna, 59901
- Har inte rekryterat ännu
- Logan Health Research - Kalispell
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Missoula, Montana, Förenta staterna, 59804
- Har inte rekryterat ännu
- Boeson Research - Missoula
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Nevada
-
Las Vegas, Nevada, Förenta staterna, 89128
- Har inte rekryterat ännu
- Palm Research Center
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
New Mexico
-
Albuquerque, New Mexico, Förenta staterna, 87102
- Har inte rekryterat ännu
- Albuquerque Clinical Trials
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
New York
-
Brooklyn, New York, Förenta staterna, 11215
- Upphängd
- Ellipsis Research Group - Brooklyn
-
-
North Carolina
-
Fayetteville, North Carolina, Förenta staterna, 28304
- Upphängd
- Javara Inc. - Cape Fear Valley Medical Center
-
Greensboro, North Carolina, Förenta staterna, 27408
- Upphängd
- PharmQuest Life Sciences
-
Morehead City, North Carolina, Förenta staterna, 28557
- Upphängd
- Centricity Research - Morehead City
-
-
Ohio
-
Canton, Ohio, Förenta staterna, 44718
- Upphängd
- Diabetes & Endocrinology Associates of Stark County
-
Maumee, Ohio, Förenta staterna, 43537
- Upphängd
- Advanced Medical Research - Maumee
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Förenta staterna, 73134
- Upphängd
- Tekton Research Oklahoma City
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Förenta staterna, 15236
- Upphängd
- Preferred Primary Care Physicians-Pittsburgh-63932
-
Uniontown, Pennsylvania, Förenta staterna, 15401
- Upphängd
- Preferred Primary Care Physicians - Matthew Drive
-
-
South Carolina
-
Bluffton, South Carolina, Förenta staterna, 29910
- Har inte rekryterat ännu
- PanAmerican Clinical Research - Bluffton
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Spartanburg, South Carolina, Förenta staterna, 29303
- Avslutad
- Spartanburg Medical Research
-
-
Tennessee
-
Chattanooga, Tennessee, Förenta staterna, 37411
- Upphängd
- University Diabetes & Endocrine Consultants
-
Memphis, Tennessee, Förenta staterna, 38115
- Har inte rekryterat ännu
- LifeDoc Research, PLLC
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Texas
-
Austin, Texas, Förenta staterna, 78731
- Upphängd
- Texas Diabetes and Endocrinology - Central Austin
-
Brownsville, Texas, Förenta staterna, 78520
- Upphängd
- South Texas Research Institute - Brownsville
-
Conroe, Texas, Förenta staterna, 77384
- Upphängd
- Privia Medical Group Gulf Coast, PLLC
-
Dallas, Texas, Förenta staterna, 75390-8837
- Har inte rekryterat ännu
- University of Texas Southwestern Medical Center
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Georgetown, Texas, Förenta staterna, 78626
- Upphängd
- Pinnacle Clinical Research - Georgetown
-
Houston, Texas, Förenta staterna, 77089
- Har inte rekryterat ännu
- Research Physicians Network
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
Houston, Texas, Förenta staterna, 77084
- Upphängd
- Biopharma Informatic, Inc. Research Center
-
Mesquite, Texas, Förenta staterna, 75149
- Har inte rekryterat ännu
- Southern Endocrinology Associates
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
San Antonio, Texas, Förenta staterna, 78222
- Upphängd
- Pinnacle Clinical Research - San Antonio
-
San Antonio, Texas, Förenta staterna, 78229
- Upphängd
- Pinnacle Clinical Research, LLC
-
Shavano Park, Texas, Förenta staterna, 78231
- Har inte rekryterat ännu
- Consano Clinical Research
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84117
- Upphängd
- Olympus Family Medicine
-
-
Virginia
-
Newport News, Virginia, Förenta staterna, 23606
- Har inte rekryterat ännu
- Tidewater Physicians Multispecialty Group
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 833-602-2368
- E-post: unitedstates@bitrialsupport.com
-
-
Washington
-
Redmond, Washington, Förenta staterna, 98052
- Upphängd
- ERA Health Research - Redmond
-
-
-
-
-
Ahmedabad, Indien, 380006
- Har inte rekryterat ännu
- Gujarat Endocrine Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Ahmedabad, Indien, 380006
- Har inte rekryterat ännu
- Sardar Vallabhbhai Patel Institute of Medical Sciences and Research
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Bhubaneswar, Indien, 751019
- Har inte rekryterat ännu
- AIIMS Bhubaneshwar
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Cuttack, Indien, 753007
- Har inte rekryterat ännu
- S.C.B. Medical College & Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Hyderabad, Afzalgunj, Indien, 500012
- Har inte rekryterat ännu
- Osmania Medical College & Hospital
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Kolhāpur, Indien, 416003
- Har inte rekryterat ännu
- Shree Mahalaxmi Diatone Institute
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Lucknow, Indien, 226 014
- Har inte rekryterat ännu
- Sanjay Gandhi Post Graduate Institute of Medical Sciences
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Nagpur, Indien, 440010
- Har inte rekryterat ännu
- Diabetes Care and Research Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Nashik, Indien, 422002
- Har inte rekryterat ännu
- Supe Heart & Diabetes Hospital & Research Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
New Delhi, Indien, 110029
- Har inte rekryterat ännu
- AIIMS, New Delhi
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Pune, Indien, 411004
- Har inte rekryterat ännu
- Deenanath Mangeshkar Hospital and Research Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Trivandrum, Indien, 695032
- Har inte rekryterat ännu
- Jothydev's Diabetes Research Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
Visakhapatnam, Indien, 530040
- Har inte rekryterat ännu
- Vishakha Institute of Medical Sciences
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0008000501442
- E-post: india@bitrialsupport.com
-
-
-
-
-
Québec, Kanada, G1G 5X1
- Rekrytering
- Recherche Clinique Sigma Inc.
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
-
British Columbia
-
New Westminster, British Columbia, Kanada, V3L 3W4
- Rekrytering
- Fraser Clinical Trials
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
-
Ontario
-
Brampton, Ontario, Kanada, L6S 0C6
- Rekrytering
- Centricity Research (Brampton)
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
Concord, Ontario, Kanada, L4K 4M2
- Rekrytering
- Centricity Research (Vaughan)
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
Nepean, Ontario, Kanada, K2J 0V2
- Rekrytering
- Centricity Research (Nepean)
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
Toronto, Ontario, Kanada, M6G 1M2
- Rekrytering
- Diabetes Heart Research Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
Toronto, Ontario, Kanada, M4G 3E8
- Rekrytering
- Centricity Research (Bayview)
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
Toronto, Ontario, Kanada, M9V 4B4
- Rekrytering
- Albion Finch Medical Centre
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
-
Quebec
-
Montreal, Quebec, Kanada, H4A 3T2
- Rekrytering
- Applied Medical Informatics Research Inc.
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
Montreal, Quebec, Kanada, H4J 1E3
- Rekrytering
- Endocrinologie Oasis Inc
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 18336022346
- E-post: canada@bitrialsupport.com
-
-
-
-
-
Auckland, Nya Zeeland, 0626
- Rekrytering
- Waitemata Clinical Research
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0800440725
- E-post: newzealand@bitrialsupport.com
-
Hamilton, Nya Zeeland, 3204
- Rekrytering
- Clinical Trials New Zealand Ltd
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0800440725
- E-post: newzealand@bitrialsupport.com
-
-
Dunedin
-
Central Dunedin, Dunedin, Nya Zeeland, 9016
- Rekrytering
- Momentum Clinical Research Dunedin
-
Kontakt:
- Boehringer Ingelheim
- Telefonnummer: 0800440725
- E-post: newzealand@bitrialsupport.com
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion criteria:
-
Male or female, age ≥18 years at the time of signing informed consent, and at least the legal age of consent in countries where it is >18 years
-
Diagnosed with type 2 diabetes mellitus (T2D) (e.g. American diabetes association (ADA)/European association for the study of diabetes (EASD) guidelines) and must meet requirements for one of background therapy parts A, B or C:
- Part A: Naïve to insulin therapy and have not used oral or injectable anti-hyperglycaemic (diabetes) medication for at least 90 days prior to screening (Visit 1) and glycosylated haemoglobin A1c (HbA1c) ≥7.0 (≥53 mmol/mol) and <9.5% (<80 mmol/mol) as measured by the central laboratory at screening (Visit 1);
- Part B: Treated with stable dose of oral antidiabetic medication (OAD) for 90 days prior to screening (Visit 1) as monotherapy or combination of: Maximum tolerated dose of metformin and/or Maximum tolerated dose of sulfonylurea and/or Maximum tolerated dose of sodium-glucose cotransporter 2 inhibitor (SGLT2i) and HbA1c ≥7.0% (≥53 mmol/mol) and <10.5% (<91 mmol/mol) as measured by the central laboratory at screening (Visit 1);
- Part C: Stable use of basal insulin at a dose of ≥20 international units (IU)/day with or without stable dose of metformin and/or SGLT2i for 90 days prior to screening (Visit 1) and HbA1c ≥7.0% (≥53 mmol/mol) and <10.5% (<91 mmol/mol) as measured by the central laboratory at screening (Visit 1)
-
Body mass index (BMI) ≥23 kg/m2 at screening (Visit 1)
-
Signed and dated written informed consent in accordance with international council for harmonisation - good clinical practice (ICH-GCP) and local legislation prior to admission to the trial
-
Woman (or women) of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control per international council for harmonisation of technical requirements for pharmaceuticals for human use M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly.
-
In the investigator's opinion, participants are well-motivated, capable, and willing to: Learn how to self-inject the investigational medicinal product (IMP), as required for this protocol (persons with physical limitations who are not able to perform the injections must have the assistance of an individual trained to inject the IMP); Inject the IMP or accept injection from a designated person; Follow study procedures for the duration of the study, including, but not limited to: follow lifestyle advice (for example, dietary restrictions and exercise plan), maintain a diary, complete required questionnaires, and handle the IMP as described in the instructions for use (IFU)
Exclusion criteria:
- Type 1 diabetes mellitus (T1D) or latent autoimmune diabetes in adults (LADA)
- Treatment within 90 days before screening (Visit 1) up to and including randomisation (Visit 2) with any: glucagon-like peptide-1 receptor (GLP-1R) agonists including GLP-1R agonist/glucose-dependent insulinotropic polypeptide (GIP) combinations, amylin or incretin combinations; Glucose-lowering drugs other than stated in the inclusion criteria for each part (i.e. metformin, Sodium-Glucose Cotransporter 2 Inhibitor (SGLT2i), basal insulin, depending on the background therapy part); Glucose-lowering investigational drug; Any anti-obesity medication including bupropion/naltrexone, orlistat, phentermine, and phentermine/topiramate
- History of ketoacidosis or hyperosmolar state or coma within the last 6 months before screening (Visit 1) up to and including randomisation (Visit 2)
- Hypoglycaemia unawareness or a history of severe hypoglycaemia within the last 3 months before screening (Visit 1) up to and including randomisation (Visit 2)
- Diabetic retinopathy or maculopathy currently under treatment, or that is reasonably anticipated to require such treatment over the duration of the study
- Body weight change (self-reported) >5% within 90 days before screening (Visit 1)
- Previous or planned (during the trial period) treatment for obesity with surgery or a weight loss device, including any prior bariatric surgery. The following are allowed: (1) liposuction and/or abdominoplasty, if performed >1 year before screening (Visit 1), (2) lap banding, if the band has been removed >1 year before screening (Visit 1), (3) intragastric balloon, if the balloon has been removed >1 year before screening (Visit 1), (4) duodenal-jejunal bypass sleeve, if the sleeve has been removed >1 year before screening (Visit 1).
- Answered "yes" to any of the suicide-related behaviours (Actual attempt, Interrupted attempt, Aborted attempt, Preparatory act or behaviour) or to the non-suicidal self-injurious behaviour question on the "Suicidal Behaviour" section of the Columbia-Suicide Severity Rating Scale (C-SSRS) related to the past 2 years before screening (Visit 1) up to and including randomisation (Visit 2)
- Further exclusion criteria apply.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Fyrdubbla
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Placebo-jämförare: Part A: Placebo
Placebo as an add-on to diet and exercise. |
Placebo |
|
Experimentell: Part A: Low-dose survodutide
Low-dose survodutide as an add-on to diet and exercise. |
Survodutide
Andra namn:
|
|
Experimentell: Part A: High-dose survodutide
High-dose survodutide as add-on to diet and exercise |
Survodutide
Andra namn:
|
|
Placebo-jämförare: Part B: Placebo
Placebo as an add-on to anti-diabetic drugs. |
Placebo |
|
Experimentell: Part B: Low-dose survodutide
Low-dose survodutide as an add-on to anti-diabetic drugs. |
Survodutide
Andra namn:
|
|
Experimentell: Part B: High-dose survodutide
High-dose survodutide as an add-on to anti-diabetic drugs. |
Survodutide
Andra namn:
|
|
Placebo-jämförare: Part C: Placebo
Placebo as an add-on to basal insulin therapy with or without anti-diabetic drugs. |
Placebo |
|
Experimentell: Part C: Low-dose survodutide
Low-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs. |
Survodutide
Andra namn:
|
|
Experimentell: Part C: High-dose survodutide
High-dose as an add-on to basal insulin therapy with or without anti-diabetic drugs. |
Survodutide
Andra namn:
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Tidsram |
|---|---|
|
Absolute change in glycosylated haemoglobin A1c (HbA1c) (%) from baseline to Week 41
Tidsram: At baseline and Week 41.
|
At baseline and Week 41.
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Key secondary endpoint: Absolute change in HbA1c (%) from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Key secondary endpoint: Achievement of HbA1c <6.5% (yes/no) at Week 41
Tidsram: At baseline and Week 41.
|
At baseline and Week 41.
|
|
|
Achievement of HbA1c <5.7% (yes/no) at Week 41
Tidsram: At Week 41.
|
At Week 41.
|
|
|
Absolute change in fasting plasma glucose (mg/dL) from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Percent change in body weight (kg) from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Relative change in non-HDL (high-density lipoprotein) cholesterol from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Relative change in triglycerides from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Relative change in urinary albumin-to-creatinine ratio (UACR) from baseline to Week 53 as a continuous variable
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Absolute change in systolic blood pressure (SBP, mmHg) from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Part C: Absolute change in daily basal insulin dose from baseline to Week 53
Tidsram: At baseline and Week 53.
|
At baseline and Week 53.
|
|
|
Estimated glomerular filtration rate (CKD-EPIcr) slope of change from baseline to Week 53
Tidsram: At baseline and Week 53.
|
CKD-EPIcr: Chronic Kidney Disease Epidemiology Collaboration creatinine equation |
At baseline and Week 53.
|
Samarbetspartners och utredare
Sponsor
Publikationer och användbara länkar
Användbara länkar
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- 1404-0115
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g. studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing
Tidsram för IPD-delning
One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.
Kriterier för IPD Sharing Access
For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .